PL2562160T3 - Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu - Google Patents

Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu

Info

Publication number
PL2562160T3
PL2562160T3 PL11765738T PL11765738T PL2562160T3 PL 2562160 T3 PL2562160 T3 PL 2562160T3 PL 11765738 T PL11765738 T PL 11765738T PL 11765738 T PL11765738 T PL 11765738T PL 2562160 T3 PL2562160 T3 PL 2562160T3
Authority
PL
Poland
Prior art keywords
agent
urine collection
therapeutic agent
preventive
disorder
Prior art date
Application number
PL11765738T
Other languages
English (en)
Inventor
Nana Hareyama
Satoru Yoshikawa
Kaoru Nakao
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2562160T3 publication Critical patent/PL2562160T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL11765738T 2010-03-31 2011-03-31 Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu PL2562160T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010083723 2010-03-31
EP11765738.7A EP2562160B1 (en) 2010-03-31 2011-03-31 Therapeutic agent or preventive agent for urine collection disorder
PCT/JP2011/058220 WO2011125838A1 (ja) 2010-03-31 2011-03-31 蓄尿障害の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
PL2562160T3 true PL2562160T3 (pl) 2015-03-31

Family

ID=44762776

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11765738T PL2562160T3 (pl) 2010-03-31 2011-03-31 Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu

Country Status (13)

Country Link
US (1) US8642625B2 (pl)
EP (1) EP2562160B1 (pl)
JP (1) JP5783042B2 (pl)
KR (1) KR101739879B1 (pl)
CN (1) CN102812008B (pl)
AU (1) AU2011237074B2 (pl)
BR (1) BR112012022944B1 (pl)
CA (1) CA2793730C (pl)
ES (1) ES2524400T3 (pl)
MX (1) MX2012010766A (pl)
PL (1) PL2562160T3 (pl)
RU (1) RU2559318C2 (pl)
WO (1) WO2011125838A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103922928A (zh) * 2013-10-31 2014-07-16 北京利和知信科技有限公司 适用于制备烯烃聚合催化剂的环取代醚酸酯化合物
JP6447496B2 (ja) * 2014-01-29 2019-01-09 東レ株式会社 多発性硬化症の治療剤又は予防剤
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
US11921476B2 (en) 2020-08-04 2024-03-05 Marathon Petroleum Company Lp Systems and methods for holistic low carbon intensity fuel and ethanol production
US11994259B2 (en) 2022-10-21 2024-05-28 Marathon Petroleum Company Lp Renewable diesel interface recombination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830728T2 (de) 1997-04-11 2006-05-18 Nippon Shinyaku Co., Ltd. Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AU4308300A (en) * 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
WO2007111323A1 (ja) * 2006-03-27 2007-10-04 Toray Industries, Inc. ウレイド誘導体およびその医薬用途
EP2061775A2 (en) * 2006-09-13 2009-05-27 Astra Zeneca AB Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
WO2008105383A1 (ja) 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
WO2010007943A1 (ja) * 2008-07-17 2010-01-21 旭化成ファーマ株式会社 含窒素複素環化合物
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途

Also Published As

Publication number Publication date
MX2012010766A (es) 2012-10-15
JPWO2011125838A1 (ja) 2013-07-11
BR112012022944B1 (pt) 2021-08-31
EP2562160A1 (en) 2013-02-27
BR112012022944A2 (pt) 2018-05-22
CN102812008B (zh) 2015-01-07
AU2011237074B2 (en) 2014-10-02
AU2011237074A1 (en) 2012-10-18
ES2524400T3 (es) 2014-12-09
US20130041157A1 (en) 2013-02-14
JP5783042B2 (ja) 2015-09-24
RU2012146323A (ru) 2014-05-10
CN102812008A (zh) 2012-12-05
KR20130052537A (ko) 2013-05-22
EP2562160B1 (en) 2014-09-10
EP2562160A4 (en) 2013-08-07
WO2011125838A1 (ja) 2011-10-13
CA2793730A1 (en) 2011-10-13
KR101739879B1 (ko) 2017-05-25
RU2559318C2 (ru) 2015-08-10
CA2793730C (en) 2017-10-17
US8642625B2 (en) 2014-02-04

Similar Documents

Publication Publication Date Title
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
IL222702A0 (en) Incontinence treatment
EP2548517A4 (en) CATHETER FOR ENDOSCOPE
EP2448809A4 (en) TRACK SYSTEM
GB2478797B (en) Waste treatment
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
HK1247207A1 (zh) 可治療癌症和其他疾病的新化合物
EP2510949A4 (en) THERAPEUTICS FOR FIBROMYALGIA
GB201109205D0 (en) Urine shield
ZA201301458B (en) Therapeutic agent for pain
PL2562160T3 (pl) Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu
EP2601954A4 (en) THERAPEUTIC FOR DISEASES
IL224340A (en) Sanitary cause
EP2486929A4 (en) ANTI-TUMOR THERAPEUTIC AGENT
GB0901465D0 (en) Compounds for use in therapy
ZA201203961B (en) Improved oestrus detector
GB2475242B (en) Mounted medical device track system
ZA201201894B (en) Pharmaceutical combination for treating tumor
PL2566579T3 (pl) Urządzenie medyczne do magnetoterapii
IL218495A0 (en) Theraputic agent for chronic pain
GB2486713B (en) Pharmaceutical composition for treating urinary system disorders
TWM400880U (en) Treatment device for waste solution
EP2409719A4 (en) DETECTOR FOR INCONTINENCE
TWM388337U (en) Defecation bed device for nursing
GB0920942D0 (en) Agent for treating disease